RanaBio is developing a state-of-art technology for producing site-specifically modified proteins. These modifications can be phosphorylation, glycosylation, methylation, and chemically reactive handles. The technology is further developed and commercialized as a set of research tools, which are easy-to-use and are broadly applicable to any expression systems and protein targets.
Our mission is to provide innovative products and high quality service for life science research community. The strategy is to simplify complicated Chemistry and Biochemistry used in generation of modified proteins so that easy-to-use products can be developed and commercialized.
With the support of SBIR funding from NIH, we are developing and optimizing translation systems for producing site-specifically phosphorylated proteins. We have established a cell-free platform for the incorporation of non-natural amino acids into proteins.
We also work with partners developing novel protein conjugation chemistry and generating cell lines for protein production.
We currently offer custom synthesis of phosphoproteins. These proteins will be produced in an E. coli based translation system. Phosphorylation will be incorporated at sites designated by customers.
The protein phosphorylation is the result of the incorporation of phosphoamino acids at the designated sites. We have developed a translation system that allows incorporation of phosphoamino acids site-specifically. No kinases are needed.
Corresponding non-phosphorylated protein will also be produced in parallel. Protein purification will be conducted based on characteristics of individual proteins and the availability of fusion tags. The purity is assessed on SDS-PAGE gels. The phosphorylation or phospho-content will be analyzed with IEF (iso-electric focusing) electrophoresis, 2D-PAGE, or Mass spec analysis.
Rana Bioscience, Inc. has not received any reviews.
Rana Bioscience, Inc. has not received any endorsements.